tbuckley/cabot-search huggingface dataset:
INNV-34. PATTERNS OF FAILURE AND DEVELOPMENT OF A NOVEL PROGNOSTIC SCORING SYSTEM IN ELDERLY PATIENTS WITH GLIOBLASTOMA – FOLLOW UP ON 10 YEAR ANALYSIS OF THE BC CANCER AGENCY POPULATION
Authors: Jonathan Zeng, Kimberly DeVries, Andra Krauze
Journal: Neuro-Oncology (2019)

Abstract PURPOSE Glioblastomas (GBM) are the most common primary brain tumour recurring in most patients despite maximal management. Patient selection for appropriate treatment modality remains challenging resulting in heterogeneity in management. We examined the patterns of failure and developed a scoring system for patient stratification to optimise clinical decision making. METHODS 822 adults (BC Cancer Agency registry) diagnosed 2005–2015 age ≥60 with histologically confirmed GBM ICD-O-3 codes (9440/3, 9441/3, 9442/3) were reviewed. Univariate and Kaplan-Meier analysis were performed. Performance status (PS), age and resection status were assigned a score, cummulative maximal (favorable) score of 10 and minimum (unfavorable) score of 3. Patterns of failure were further analysed in the subset of patients with radiographic follow-up. RESULTS PS score of 3(KPS &gt;80, ECOG 0/1), 2 (KPS 60–70, ECOG 2), 1 (KPS &lt; 60, ECOG 3/4) (median OS 11, 6, 3 months respectively), age score and resection status were prognostic for OS with PS resulting in the most significant curve separation (p&lt; 0.0001). Biopsy as compared to STR/GTR resulted in poorer OS in patients over 70 (age score 1/2) but had less impact in patients younger than 70 (age scores 3/4). The median OS for cumulative scores of 9/10 (123 patients), 7/8 (286 patients), 5/6 (313 patients), and 3/4 (55 patients) were 14, 8, 4 and 2 months respectively (p&lt; 0.0001) allowing for stratification into 4 prognostic groups. 133 patients had &gt;3 MRIs following diagnosis allowing for clinical and radiographic analysis of progression. Clinical/radiographic progression occurred within 3 months (29%/45%), 6 months (50%/66%), 9 months (70%/81%). Progression type (radiographic, clinical, both was not associated with OS. CONCLUSION Our novel prognostic scoring system is effective in achieving patient stratification and may guide clinical decision making. Early radiographic progression appears to precede clinical deterioration and may represent true progression in the elderly.
Ixazomib-Based Frontline Therapy in Patients with Newly Diagnosed Multiple Myeloma in Real-Life Practice Showed Comparable Efficacy and Safety Profile with Those Reported in Randomized Clinical Trials: A Multi-Center Study in China
Authors: Jing Li, Li Bao, Zhong-jun Xia, Sili Wang, Xin Zhou, Kaiyang Ding, Wenhao Zhang, Wei Yang, Bingzong Li, Zhengzheng Fu, Bing Chen, Luoming Hua, Liang Wang, Luo Jun, Yang Yang, Tianhong Xu, Weida Wang, Yun Huang, Guolin Wu, Peng Liu
Journal: Blood (2019)
Preventing dysbiosis of the neonatal mouse intestinal microbiome protects against late-onset sepsis
Authors: Jeffrey R. Singer, Emily G. Blosser, Carlene L. Zindl, Daniel J. Silberger, Sean Conlan, Vincent A. Laufer, Daniel DiToro, Clay Deming, Ranjit Kumar, Casey D. Morrow, Julia A. Segre, Michael J. Gray, David A. Randolph, Casey T. Weaver
Journal: Nature Medicine (2019)
ATIM-45. LONG TERM FOLLOW-UP OF A PHASE I/II STUDY TESTING THE TOXICITIES AND EFFICACY OF PEMBROLIZUMAB IN COMBINATION WITH MRI-GUIDED LASER INTERSTITIAL THERMAL THERAPY (LITT) IN RECURRENT MALIGNANT GLIOMAS
Authors: Jian Campian, Ashley Ghiaseddin, Maryam Rahman, Jiayi Huang, George Ansstas, Albert Kim, Eric Leuthardt, David Tran
Journal: Neuro-Oncology (2019)

Abstract BACKGROUND LITT was recently demonstrated to induce temporary blood-brain barrier disruption, possibly allowing bilateral trafficking of tumor neoantigens and immune cells to induce glioma-specific immune activation - a phenomenon akin to in situ tumor vaccination. We hypothesize that combining LITT with immune checkpoint inhibition will create a synergistic therapy for recurrent GBM. METHODS The phase 1 study is a standard 3x3 design with a maximum of 18 patients with bevacizumab-naïve recurrent WHO grade 3–4 glioma. The primary endpoint is safety and toxicity of LITT plus pembrolizumab at 100, 150, or 200mg IV q3weeks. Phase 2 includes 40 patients with bevacizumab-naïve recurrent GBM, equally randomized to either pembrolizumab alone or LITT plus pembrolizumab, with progression-free survival as the primary endpoint. Serial immunophenotyping will be performed to evaluate potential positive synergy between LITT and pembrolizumab. RESULTS Phase 1 accrual was completed with 9 patients (3 at each pembrolizumab dose level). Two had recurrent anaplastic astrocytoma and 7 recurrent GBM. There was no dose-limiting toxicity with pembrolizumab 200mg IV q3weeks. The median number of doses given per patient was 9 (range 2 to 47). Severe adverse events possibly related to the study treatment included a grade 3 rash and diarrhea in 1 patient (11%) and grade 3 pneumonitis and hypotension in another patient (11%). No grade 3/4 intracranial edema deemed related to study treatment was observed. To date, four (44%) of these patients are still alive without tumor progression. Two (22%) GBM patients have not progressed for 29 and 33 months, respectively. Two (22%) anaplastic astrocytoma patient have not progressed for 23 and 24 months, respectively. CONCLUSIONS LITT plus pemprolizumab 200mg IV q3weeks is well tolerated in patients with recurrent high-grade glioma. Prolonged stable diseases were observed in almost half of patients treated. Phase 2 study is ongoing and will be updated.
Oryzocytosis: A Novel Morphological Variant of Hereditary Elliptocytosis Associated with a Novel Mutation in β-Spectrin (SPTB c154 C&amp;gt;T p.Arg52Trp)
Authors: Alexander Glaros, Manisha Gadgeel, Shruti Bagla, Steven Buck, Roland Chu, Yaddanapudi Ravindranath, Brian Edwards, Asmita Vaishnav
Journal: Blood (2019)
NIMG-33. TUMOR GROWTH AND MRI TRAJECTORIES IN GRADE II AND III GLIOMA
Authors: Tracy Luks, Yan Li, Paula Alcaide-Leon, Marisa Lafontaine, Angela Jakary, Susan Chang, Javier Villanueva-Meyer
Journal: Neuro-Oncology (2019)

Abstract INTRODUCTION The purpose of this work was to investigate the trajectory of tumor growth and multiparametric MRI characteristics in grade II and III gliomas leading up to the onset of new contrast enhancement or the expansion of FLAIR signal abnormality. METHODS Fifty-one grade II and III glioma patients (39 grade II, 12 grade III) underwent serial MR imaging at standard of care timepoints. Multiparametric MR imaging was performed and maps of the apparent diffusion coefficient (ADC) and percentiles (10th, 50th, 90th) from histograms of normalized signal intensities were calculated. Regions of Interest (ROIs) were defined for the entire T2/FLAIR lesion, and when present, the contrast-enhancing (CE) lesion. Serial imaging parameters were acquired for each of these ROIs. Linear rates of change were calculated for CE volume, T2/FLAIR volume, normalized T2 FSE intensity within the FLAIR volume, normalized T2/FLAIR intensity within the FLAIR volume, and normalized median, 10th percentile and 90th% ADC values within the FLAIR volume. RESULTS Thirty-nine patients progressed while on study (7 by CE growth, 32 by T2/FLAIR growth), and 12 patients remained stable, according to RANO criteria. In progressed patients, T2/FLAIR volume and T2 FSE intensity increased over time to progression. The rate of T2/FLAIR volume growth was significantly greater in progressed than stable patients (mean = .42, -.07 mL/week, respectively). The rate of normalized T2/FLAIR signal intensity change was also significantly different in progressed than stable patients (mean = -.002, .0035 mL/week). There were no significant interactions with grade or molecular subgroup by WHO criteria. Additionally, 44% (17/39) of progressed patients by RANO criteria were characterized as having stable disease by radiologic assessment. CONCLUSION Tumor volumes remain the gold standard for response assessment in lower grade gliomas and there exists a need for standardized measurement as visual assessment for determination of tumor status is inconsistent.
Evaluation of Minnelide As a Potential Therapeutic Agent for Preventing the Relapse of AML
Authors: Pooja Roy, Bhuwan Giri, Vanessa Tonin Garrido, Dujon Brandon Edwards, Justin M. Watts, Sulagna Banerjee, Vikas Dudeja, Sundaram Ramakrishnan, Ashok Saluja
Journal: Blood (2019)
A Randomized, Double-Blind, Placebo-Controlled, Phase II Study of MBG453 Added to Hypomethylating Agents (HMAs) in Patients (pts) with Intermediate, High, or Very High Risk Myelodysplastic Syndrome (MDS): Stimulus-MDS1
Authors: Amer M Zeidan, Yasushi Miyazaki, Uwe Platzbecker, Kamel Malek, Julie Niolat, Flavia Kiertsman, Pierre Fenaux
Journal: Blood (2019)
Modified Anti-FXa Assays for Measuring the Residual Activity of Apixaban and Rivaroxaban in Andexanet Alfa-Containing Samples on the ACL TOP Family® Coagulation Analyzers
Authors: Anuja Khan, Krisjela Shishko, Sam Arcidiacono, Khanh Bui, Genmin Lu, Pamela B. Conley, Anne Winkler
Journal: Blood (2019)
High Sensitivity NGS Analysis of MRD in CLL Patients Prospectively Treated with Ibrutinib Plus FCR (iFCR)
Authors: Alexander R. Vartanov, Stacey M. Fernandes, Winnie I Nguy, Danielle M. Brander, Svitlana Tyekucheva, Alexandra Savell, Allison P. Jacob, Jon E. Arnason, Jeremy S. Abramson, Matthew S. Davids, Jennifer R. Brown
Journal: Blood (2019)
Misleading information about Lyme disease
Authors: Stella R Huyshe-Shires
Journal: BMJ (2019)

I’m glad to see the Science Media Centre briefing journalists about Lyme disease. Hopefully this will reduce the publication of articles featuring patients receiving diagnoses from private overseas laboratories.1 Many articles have misled people, and Lyme Disease Action is often contacted by distressed patients who find that their diagnosis is not accepted by their general practitioner.

The briefing itself, however, might …
The Scenario of Myelofibrosis in Brazil in the View of a Panel of Experts: Challenges and Proposals
Authors: Laura Maria Fogliatto, Cristiana Solza, Alexandre Gustavo Apa, Gustavo HR Magalhaes, Marcia Torresan Delamain, Renato Tavares, Lorena Lobo Figueiredo-Pontes
Journal: Blood (2019)
RIG-I-based immunotherapy enhances survival in preclinical AML models and sensitizes AML cells to checkpoint blockade
Authors: Michael Ruzicka, Lars M. Koenig, Simone Formisano, Daniel F. R. Boehmer, Binje Vick, Eva-M. Heuer, Hanna Meinl, Lorenz Kocheise, Marcus Zeitlhöfler, Julia Ahlfeld, Sebastian Kobold, Stefan Endres, Marion Subklewe, Peter Duewell, Max Schnurr, Irmela Jeremias, Felix S. Lichtenegger, Simon Rothenfusser
Journal: Leukemia (2019)

Abstract Retinoic acid-inducible gene-I (RIG-I) is a cytoplasmic immune receptor sensing viral RNA. It triggers the release of type I interferons (IFN) and proinflammatory cytokines inducing an adaptive cellular immune response. We investigated the therapeutic potential of systemic RIG-I activation by short 5′-triphosphate-modified RNA (ppp-RNA) for the treatment of acute myeloid leukemia (AML) in the syngeneic murine C1498 AML tumor model. ppp-RNA treatment significantly reduced tumor burden, delayed disease onset and led to complete remission including immunological memory formation in a substantial proportion of animals. Therapy-induced tumor rejection was dependent on CD4 + and CD8 + T cells, but not on NK or B cells, and relied on intact IFN and mitochondrial antiviral signaling protein (MAVS) signaling in the host. Interestingly, ppp-RNA treatment induced programmed death ligand 1 (PD-L1) expression on AML cells and established therapeutic sensitivity to anti-PD-1 checkpoint blockade in vivo. In immune-reconstituted humanized mice, ppp-RNA treatment reduced the number of patient-derived xenografted (PDX) AML cells in blood and bone marrow while concomitantly enhancing CD3 + T cell counts in the respective tissues. Due to its ability to establish a state of full remission and immunological memory, our findings show that ppp-RNA treatment is a promising strategy for the immunotherapy of AML.
Severe Chronic Neutropenia in the Large Granular Lymphocyte Syndrome: Outcomes in Response to Granulocyte Colony Stimulating Factor (G-CSF) and Immunosuppressive Therapies
Authors: David C. Dale, James A. Shannon, Audrey Anna Bolyard, Jim Connelly, Daniel C. Link, Mary Ann Bonilla, Peter E. Newburger
Journal: Blood (2019)
PDCT-05. FINAL RESULTS OF THE VINILO OPEN-LABEL PHASE II RANDOMIZED TRIAL FOR PEDIATRIC LOW-GRADE GLIOMAS (pLGG) COMPARING THE COMBINATION VINBLASTINE-NILOTINIB WITH VINBLASTINE ALONE
Authors: Jacques Grill, Caroline Brard, Sue Picton, Ofelia Cruz, A Y N Schouten-vanMetteren, Astrid Marie Sehested, Nicolas Gerber, Natacha Entz-Werle, Marie-Cécile Le Deley, Volodia Dangouloff-Ros, Pascale Varlet
Journal: Neuro-Oncology (2019)

Abstract Chemotherapy is the mainstay of non-surgical treatment in pLGG but many patients progress again after the end of the first treatment. Apart from the standard carboplatin-vincristine, new regimens with less toxicity are therefore desirable. Single agent vinblastine is an established regimen. PDGFRA TKI inhibitors have shown efficacy in refractory pLGG as well. The VINILO phase I showed the feasibility of the combination of vinblastine with nilotinib at the expense of a 50% decrease of the dose of vinblastine. The phase II trial therefore compared vinblastine 6 mg/m2 weekly (standard arm) to vinblastine 3mg/m2 weekly plus nilotinib 230mg/m2/day. The primary endpoint was the PFS, analysed on the intention-to-treat population. The target sample size was 120 patients. Accrual was stopped after recruitment of 109 patients (53 and 56 in the vinblastine-arm and the vinblastine+nilotinib arm, respectively) between July 2016 and April 2019. Fifty-four patients had an optic pathway glioma and 45 had NF1 (these patients were allowed to enter the trial as initial therapy). Half of the patients were treated after more than one line of therapy. The planned interim analysis showed that the vinblastine+nilotinib arm was associated with a worse PFS as compared to the standard arm (HR=2.37; 95%CI, 1.26–4.46; p=0.007; with 2-year PFS of 28% versus 49%). Overall, 156 biological adverse events (AE) of grade ≥ 3 have been reported after randomization (94 in vinblastine alone arm, 62 in vinblastine+nilotinib arm) and 84 non-biological adverse events of grade ≥ 3 (50 in vinblastine alone arm, 34 in vinblastine+nilotinib arm). We conclude that the combination of vinblastine plus nilotinib was less effective than vinblastine alone, possibly because of a lower dose intensity of vinblastine in the experimental arm. Vinblastine can serve as a backbone for combinations but lowering its dose may jeopardize the efficacy.
Treatment Outcomes with Purine Nucleoside Analog Alone or with Rituximab for Hairy Cell Leukemia Patients at First Relapse: A Multi-Center Outcomes Analysis
Authors: Rachel Hu, Wei Wei, Kristen Gonter-Aubin, Javier Pinilla Ibarz, Charlene C. Kabel, Anthony R. Mato, Yazan F. Madanat, Sirin Khajavian, Mazyar Shadman, Ashley Hanlon, Danielle M. Brander, Jae H. Park, Martin S. Tallman, Brian T. Hill
Journal: Blood (2019)
Challenging the Association of Marijuana Laws With Teen Marijuana Use—Reply
Authors: D. Mark Anderson, Daniel I. Rees, Joseph J. Sabia
Journal: JAMA Pediatrics (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Pediatrics HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Pediatrics journal
Healthcare system encounters before COPD diagnosis: a registry-based longitudinal cohort study
Authors: Kate M Johnson, Amir Khakban, Stirling Bryan, Don D Sin, Mohsen Sadatsafavi
Journal: Thorax (2019)

Background There is high interest in strategies for improving early detection of chronic obstructive pulmonary disease (COPD). These strategies often rely on opportunistic encounters between patients with undiagnosed COPD and the healthcare system; however, the frequency of these encounters is currently unknown. Methods We used administrative health data for the province of British Columbia, Canada, from 1996 to 2015. We identified patients with COPD using a validated case definition, and assessed their visits to pharmacists, primary care and specialist physicians in the 5 years prior to the initial diagnosis of COPD. We used generalised linear models to compare the rate of outpatient visits between COPD and non-COPD comparator subjects matched on age, sex and socioeconomic status. Results We assessed 112 635 COPD and non-COPD pairs (mean 68.6 years, 51.0% male). Patients with COPD interacted with pharmacists most frequently in the 5 years before diagnosis (mean 14.09, IQR 4–17 visits/year), followed by primary care (10.29, IQR 4–13 visits/year) and specialist (8.11, IQR 2–11 visits/year) physicians. In the 2 years prior to diagnosis, 72.1% of patients with COPD had a respiratory-related primary care visit that did not result in a COPD diagnosis. Compared with non-COPD subjects, patients with COPD had higher rates of primary care (rate ratio (RR) 1.40, 95% CI 1.39 to 1.41), specialist (RR 1.35, 95% CI 1.34 to 1.37) and pharmacist (RR 1.62, 95% CI 1.60 to 1.63) encounters. Conclusions Patients with COPD used higher rates of outpatient services before diagnosis than non-COPD subjects. Case detection technologies implemented in pharmacy or primary care settings have opportunities to diagnose COPD earlier.
Impact of Daratumumab Monotherapy on Bone Parameters in Patients with Relapsed and/or Refractory Multiple Myeloma Who Have Received at Least 2 Prior Lines of Therapy Including Lenalidomide and a Proteasome Inhibitor; Interim Analysis of a Phase 2 Study (the REBUILD Study)
Authors: Evangelos Terpos, Eftathios Kastritis, Evdoxia Hatjiharissi, Eirini Katodritou, Evangelos Eleutherakis-Papaiakovou, Evgenia Verrou, Maria Gavriatopoulou, Alexandros Leonidakis, Ioannis Ntanasis-Stathopoulos, Sosana Delimpasi, Marie-Christine Kyrtsonis, Maria Papaioannou, Argiris Symeonidis, Meletios A. Dimopoulos
Journal: Blood (2019)
Effects of the guanine-quadruplex telomerase inhibitor BRACO-19 on tumour cells: Evidence of selective action on telomere maintenance
Authors: Keizo Koya, Lijun Sun, Shoujun Chen, Noriaki Tatsuta, Timothy Korbut, Dan Zhou, Guiqing Liang, Yaming Wu, Zhenjian Du, Zhi-Qiang Xia, Thomas A. Dahl, James Barsoum, Mitsunori Ono, Lan Bo Chen
Journal: Cancer Research (2004)

1504  STA-4783 is a newly synthesized bis-thiobenzoylhydrazide compound (MW: 400) that promotes tumor-specific induction of heat shock protein 70 (HSP70) and exhibits significant enhancement of Paclitaxel efficacy in a variety of human tumor xenografts in nude mice and mouse syngeneic tumor models. Although STA-4783 exhibited little to no anti-tumor activity when administered as a single agent in these models, it dramatically increased the efficacy of both low sub-optimal doses of Paclitaxel as well as the higher maximum-tolerated doses of Paclitaxel. Both a reduction in tumor size and an increase in survival were observed. STA-4783 induced strong HSP70 expression in many tumor cell lines including human breast carcinoma MDA-435 (at 0.1 μM), but not in normal cell lines such as human mammary epithelial cells HMEC or human renal epithelial cells HREC (at 5 μM) in vitro. The substantially improved anti-tumor activity of the combination therapy was seen in mouse xenograft models with human tumors of various origins, including breast (MDA-435, MCF-7, ZR-75-1), lung (RERF), and lymphoma (U937). This enhancement in efficacy was dose-dependent with regard to STA-4783. STA-4783 co-treatment did not result in additional toxicity above that observed with Paclitaxel alone. In the detailed GLP toxicity and DMPK studies in rats and dogs, no increased toxicity was observed. STA-4783 had no influence on the pharmacokinetics of Paclitaxel. The Paclitaxel enhancement of STA-4783 was not observed in vitro and was absent in SCID-beige models in vivo, suggesting an immune-mediated mechanism. The HSP70 induction by STA-4783 in tumor cells may activate the immune system, thereby adding to the anti-tumor activity of Paclitaxel. In fact, it has been observed that treatment of tumor cells with STA-4783 and related compounds that induce HSP70, but not compounds that fail to induce HSP70, increased the lysis of tumor cells by mouse splenocytes. A phase I trial is underway to define the maximum tolerated dose, toxicity, and pharmacokinetics of STA-4783 combined with Paclitaxel.
CRISPR-Cas9 Screen Identifies XPO7 As a Potential Therapeutic Target for TP53-Mutated AML
Authors: Yuichiro Semba, Takuji Yamauchi, Fumihiko Nakao, Jumpei Nogami, Matthew C. Canver, Luca Pinello, Daniel E. Bauer, Koichi Akashi, Takahiro Maeda
Journal: Blood (2019)
Randomized Trial of Lenalidomide and Dexamethasone Versus Clarythromycin, Lenalidomide and Dexamethasone As First Line Treatment in Patients with Multiple Myeloma Not Candidates for Autologous Stem Cell Transplantation: Results of the GEM-Claridex Clinical Trial
Authors: Noemi Puig, Miguel T Hernández, Laura Rosinol Dachs, Esther González Garcia, Felipe De Arriba, Albert Oriol, Veronica Gonzalez-Calle, Fernando Escalante, Javier De La Rubia, Mercedes Gironella Meda, Rafael Ríos Tamayo, Ricarda Belen Garcia Sanchez, José María Arguiñano Pérez, Adrián Alegre Amor, Jesús Martín, Norma C. Gutierrez, Maria Jose Calasanz, Maria Luisa Martin-Ramos, María del Carmen Couto Caro, Maria Casanova, Mario Arnao, Ernesto Pérez Persona, Sebastián Garzón López, Marta Sonia Gonzalez, Guillermo Martín Sánchez, Adriana C. Rossi, Morton Coleman, Cristina Encinas, Ana María Vale López, Ana Isabel Teruel, Bruno Paiva, Maria Teresa Cedena Romero, Jesús San-Miguel, Juan Jose Lahuerta, Joan Bladé, Ruben Niesvizky, Maria-Victoria Mateos
Journal: Blood (2019)
The Impact of Allogeneic Hematopoietic Cell Transplantation (alloHCT) on the Outcome of Poor-Risk Non-Hodgkin Lymphoma (NHL): A Retrospective Intent-to-Transplant (ITT) Analysis
Authors: Lorenz Selberg, Peter Stadtherr, Sascha Dietrich, Thomas Luft, Andrea Bondong, Ute Hegenbart, Julia Meissner, Nora Liebers, Michael Schmitt, Carsten Mueller-Tidow, Peter Dreger
Journal: Blood (2019)
The Impact of a Mandatory Prescription Drug Monitoring Program (PDMP) on Opioid Prescription Among Sickle Cell Disease Patients By Emergency Medicine Physicians in Community Teaching Hospitals in Philadelphia
Authors: Sufana Shikdar, Vinay Edlukudige Edlukudige Keshava, Peter Lambert, Sindusha Gudipally, Anthony Esposito, Brad Bendesky, Eric Green
Journal: Blood (2019)
Generation and Characterisation of KY1066, a Fully Human Antibody Targeting the Enzymatic Activity of Matriptase-2 for the Treatment of Iron Overload in Beta Thalassemia
Authors: Matthew Wake, Jonathan Papworth, Luke Bayliss, Benjamin Grimshaw, Natalie Rynkiewicz, Jemima Paterson, Alicia Poindron, Erin Spearing, Emily Carter, Robyne Hudson, Verena Petzer, Amelie Largounez, Audrey Belot, Anais Palin, Igor Theurl, Volker Germaschewski, Delphine Meynard
Journal: Blood (2019)